Method for diagnosing autoimmune diseases by measuring binding strength between ETS1 and RNA splicing regulatory factors involved in t cell activity

Measuring the binding strength between ETS1 and RNA splicing regulators provides a rapid and accurate diagnostic method for autoimmune diseases by regulating T cell activity, addressing the lack of effective markers in current diagnostic methods.

WO2026235334A1PCT designated stage Publication Date: 2026-11-12UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/005820
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current diagnostic methods for autoimmune diseases, particularly systemic lupus erythematosus (SLE), lack effective molecular-based markers for early and accurate diagnosis, making it challenging to predict disease progression and manage treatment effectively.

Method used

Measuring the binding strength between the transcription factor ETS1 and RNA splicing regulators, such as Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and Setd1a, to regulate T cell activity and provide a diagnostic method for autoimmune diseases, cancer, or inflammation.

Benefits of technology

Enables rapid, accurate, and efficient diagnosis and treatment of autoimmune diseases by regulating T cell activity through the binding strength of ETS1 and RNA splicing regulators, facilitating early detection and personalized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026005820_12112026_PF_FP_ABST
    Figure KR2026005820_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for diagnosing autoimmune diseases, cancer, or inflammation, comprising an agent for measuring the binding strength between ETS1 and RNA splicing regulatory factors. In the present invention, which is directed to research for effective and accurate diagnosis of inflammatory diseases, it has been discovered that the activity and differentiation of T cells can be regulated by regulating the binding of RNA splicing regulatory factors complexed with the transcription factor ETS1 (Protein C-ets-1), thereby enabling autoimmune diseases, cancer, or inflammation to be quickly, accurately, and efficiently diagnosed using same, and thus the present invention is expected to be widely used in the medical / health fields.
Need to check novelty before this filing date? Find Prior Art

Description

Diagnostic method for autoimmune diseases through measurement of binding strength between ETS1, involved in T cell activation, and RNA splicing regulators

[0001] The present invention relates to a method for diagnosing an autoimmune disease by measuring the binding strength of ETS1, which is involved in T cell activation, and an RNA splicing regulatory factor, and a diagnostic composition using the same.

[0002] Lupus, a type of inflammatory autoimmune disease, is an inflammatory autoimmune disorder estimated to affect nearly one million Americans, primarily women aged 20 to 40. Since lupus progresses from the skin and joints to attacking internal organs including the lungs, heart, and kidneys, untreated lupus can be fatal; therefore, early and accurate diagnosis of lupus and / or risk assessment of its development are particularly important. The primary form of lupus is systemic lupus erythematosus (SLE). Clinically, SLE is a heterogeneous disorder characterized by high-affinity autoantibodies (autoAbs), which play a significant role in the pathogenesis of SLE; the various clinical manifestations of the disease are caused by the deposition of antibody-containing immune complexes within blood vessels that induce inflammation in the kidneys, brain, and skin. Systemic lupus erythematosus is associated with the production of antinuclear antibodies, circulating immune complexes, and the activation of the complement system; therefore, it can affect any organ system and cause severe tissue damage, such as glomerulonephritis, arthritis, serositis, complete cardiac block in newborns, and hematological abnormalities. One of the most challenging tasks in the clinical management of inflammatory diseases like lupus is the accurate early diagnosis of the disease in patients. Although many studies have been conducted to identify genetic factors contributing to susceptibility to systemic lupus erythematosus, molecular-based diagnostic factors associated with its various clinical, / or pathophysiological, and / or other biological markers have yet to be discovered.

[0003] Accordingly, the researchers of the present invention have completed this invention by discovering, as part of their research for the effective and accurate diagnosis of inflammatory diseases, that T cell activity can be regulated according to the binding strength of the transcription factor ETS1 (Protein C-ets-1) and RNA splicing regulators. This invention is expected to be widely utilized as a method for the early diagnosis and treatment of inflammatory autoimmune diseases.

[0004] The inventors have made diligent research efforts to accurately diagnose inflammatory diseases. As a result, they discovered that T cell activity can be regulated depending on the binding strength between the transcription factor ETS1 (Protein C-ets-1) and an RNA splicing regulator; utilizing this, the present invention has completed an effective, rapid, and accurate method for diagnosing inflammatory diseases.

[0005] Accordingly, one objective of the present invention is to provide a composition for diagnosing autoimmune diseases, cancer, or inflammation, comprising a preparation that measures the binding strength of ETS1 as a transcription factor and an RNA splicing regulator.

[0006] Another objective of the present invention is to provide a method for diagnosing an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and RNA splicing regulators in a biological sample isolated from an individual.

[0007] Another objective of the present invention is to provide a method for screening candidate substances for the treatment of autoimmune diseases, cancer, or inflammation by measuring the binding strength of ETS1 and RNA splicing regulators.

[0008] In the above composition or method, the RNA splicing regulatory factor may be one or more selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

[0009] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below.

[0010] Various embodiments described herein are described with reference to the drawings. In the following description, for a complete understanding of the invention, various specific details, such as specific forms, compositions, and processes, are described. However, specific embodiments may be practiced without one or more of these specific details, or in combination with other known methods and forms. In other examples, known processes and manufacturing techniques are not described as specific details so as not to unnecessarily obscure the invention. Reference throughout this specification to "one embodiment" or "an embodiment" means that the particular features, forms, compositions, or characteristics described in association with the embodiment are included in one or more embodiments of the invention. Accordingly, the context of "in one embodiment" or "an embodiment" expressed at various places throughout this specification does not necessarily represent the same embodiment of the invention. Additionally, particular features, forms, compositions, or characteristics may be combined in any suitable way in one or more embodiments.

[0011] Unless otherwise specifically defined in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains.

[0012] Throughout the specification, when a part is described as "including" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0013] According to one aspect of the present invention, the present invention provides a composition for diagnosing autoimmune diseases, cancer, or inflammation, comprising a preparation for measuring the binding strength of ETS1 as a transcription factor and an RNA splicing regulator.

[0014] As part of research for the effective and accurate diagnosis of inflammatory diseases, the researchers of the present invention discovered that T cell activity can be regulated according to the binding strength of the transcription factor ETS1 (Protein C-ets-1) and RNA splicing regulators, and utilizing this, they have completed an effective, rapid, and accurate diagnostic method for inflammatory diseases.

[0015] Hereinafter, the term “transcription factor” in this specification refers to a protein that participates in the transcription process in eukaryotes. Transcription factors are a group of proteins that use DNA as a blueprint to read genetic information and bind to RNA polymerase to regulate transcription. Therefore, transcription factors occupy a very important role in the process of gene expression, and many transcription factors are involved in regulating the development of multicellular organisms. They act as switches that turn the transcription of specific genes on and off according to certain signals; this switching action is involved in forming the shape of the organism and promotes cell differentiation by determining the role of the cell.

[0016] In this specification, the term “autoimmune disease” refers to a disease that manifests through autoimmunity. That is, it occurs when the immune system causes an incorrect reaction to normal chemical substances and certain cells of the body, attacking healthy cells by perceiving them as harmful. Autoimmune diseases may also be caused by lymphocytes among various types that possess receptors capable of reacting with the body's own molecules.

[0017] In this specification, the term “Systemic Lupus Erythematosus (SLE),” also known as systemic lupus erythematosus, refers to a chronic inflammatory autoimmune disease in which autoantibodies against specific proteins in the cell nucleus are produced, and the body’s own cells or tissues are destroyed due to an abnormality in the immune system. Lupus is a rheumatic disease, similar to rheumatoid arthritis; however, unlike rheumatoid arthritis, which primarily affects specific areas such as the joints, lupus targets all tissues throughout the body—including not only joints and muscles but also the skin, nervous tissue, lungs, kidneys, heart, and hematopoietic organs—making it difficult to predict the progression of the disease. Furthermore, it manifests with a wide variety of symptoms, posing significant challenges to clinical diagnosis and treatment. Diagnosis is difficult because symptoms vary greatly from patient to patient, sometimes appearing within a few weeks and other times developing slowly over several years. Early symptoms of lupus commonly include general fatigue, muscle pain, low-grade or high fever, weight loss, and hair loss—symptoms also frequently seen in other diseases. Additionally, butterfly-shaped skin rashes on both cheeks and swelling or pain in the joints may occur. As lupus progresses, major organs such as the kidneys, lungs, pleura, heart, and brain become damaged, and the condition develops into systemic symptoms affecting internal organs, causing significant suffering for the patient. Since treatment is difficult, prompt diagnosis and treatment are essential.

[0018] In this specification, the term “diagnosis” includes determining an object’s susceptibility to a specific disease or condition, determining whether an object currently has a specific disease or condition (e.g., lupus), determining the prognosis of an object with a specific disease or condition, or therametrics (e.g., monitoring the condition of an object to provide information on therapeutic efficacy). Specifically, for the purposes of the invention, the term “diagnosis” in this specification means determining whether an object currently has a specific disease or condition.

[0019] In this specification, the term “diagnostic composition” refers to an integrated mixture or device comprising means for measuring the binding strength of ETS1 as a transcription factor and an RNA splicing regulator to determine whether a subject has developed a disease or to predict the likelihood of development, and may also be expressed as a “diagnostic kit.”

[0020] In this specification, the term “ETS1 (Protein C-ets-1)” refers to the protein encoded by the ETS1 gene in humans. The protein encoded by this gene belongs to the ETS family of transcription factors, of which there are 28 ETS genes in humans and 27 in mice. ETS genes bind to DNA through a winged, spiral DNA binding motif known as the Ets domain, which specifically recognizes DNA sequences containing the GGAA / T core element. Ets1 interacts directly with various transcription factors and forms a multiprotein complex. When Ets1 interacts with other transcription factors, the final effect on transcription depends on whether the C-terminal domain is phosphorylated.

[0021] According to a specific embodiment of the present invention, the RNA splicing regulatory factor is Helz (hematopoietic lineage zinc finger protein), Ddx41 (DEAD-box helicase 41), Taf15 (TATA-box binding protein associated gactor 15), Fus (heterogeneous nuclear ribonucleoprotein P2), Rnf31 (spin finger protein 31), Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1), Hnrnpl (heterogeneous nuclear ribonucleoprotein L), Thoc4 (THO complex subunit 4 protein), Syncrip (synaptotagmin binding cytoplasmic RNA interacting protein), Srrt (serine / arginine-rich splicing factor), Tardbp (TAR DNA-binding protein), Poldip3 (DNA polymerase delta interacting protein 3), and Setd1a (SET domain containing 1A) and A1cf (APOBEC1 Complementation Factor). It is one or more proteins selected from the composed group.

[0022] Accordingly, the present invention provides a composition for diagnosing an autoimmune disease or cancer comprising a preparation for measuring the binding strength of ETS1 and an RNA splicing regulatory factor; wherein the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

[0023] The above-mentioned autoimmune disease may specifically be lupus, and more specifically, systemic lupus erythematosus (SLE), but is not limited thereto.

[0024] The RNA splicing regulatory factor may more preferably be one or more proteins selected from the group consisting of Rnf31 (ting finger protein 31), Tardbp (TAR DNA-binding protein), and Setd1a (SET domain containing 1A), but is not limited thereto.

[0025] According to the present invention, an autoimmune disease refers to a disease that can cause a systemic inflammatory response in the body. Depending on the disease, the organs or tissues affected may differ, and it may be any one selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, Behcet's disease, systemic sclerosis, polymyositis, and dermatomyositis, but is not limited thereto.

[0026] According to the present invention, inflammatory diseases refer to diseases that exhibit a pattern of frequent recurrence of systemic inflammation in the absence of autoantibodies or antigen-specific T cells. It may be any one selected from the group consisting of crystalline arthropathy (gout, pseudogout), adult-onset Still's disease (AOSD), Behcet's disease, Crohn's disease, juvenile idiopathic arthritis, and SAPHO (sacroilitis, acne, pustulosis, hyperostosis, osteitis) syndrome, but is not limited thereto.

[0027] According to the present invention, cancer refers to a disease in which cell division continues due to an unregulated cell cycle, and may be at least one selected from the group consisting of melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymphoma, gallbladder cancer, blood cancer, thyroid cancer, endocrine gland cancer, oral cancer, liver cancer, biliary tract cancer, colorectal cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain tumor, lung cancer, undifferentiated thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureteral cancer, pancreatic cancer, bone / soft tissue sarcoma, skin cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and solitary myeloma, and preferably liver cancer, biliary tract cancer, colorectal cancer, rectal cancer. It may be any one selected from the group consisting of cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain tumor, lung cancer, undifferentiated thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureteral cancer, pancreatic cancer, bone / soft tissue sarcoma, and skin cancer, but is not limited thereto.

[0028] According to another aspect of the present invention, the present invention provides a method for providing information regarding the diagnosis of an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and RNA splicing regulators in a biological sample isolated from an individual.

[0029] Here, the term “method of providing information regarding diagnosis” can be interpreted as having the same meaning as “diagnostic method.”

[0030] In the present invention, the term “biological sample” refers to any sample obtained from mammals, including humans, containing cells expressing ETS1 as the transcription factor and an RNA splicing regulatory factor, and includes, but is not limited to, tissues, organs, cells, or cell culture media. More specifically, the biological sample may be a tissue or cells derived therefrom, and most preferably, a tissue containing CD4+ T cells or CD4+ T cells derived therefrom.

[0031] According to a specific embodiment of the present invention, the binding protein is the RNA splicing regulatory factor, which is Helz (hematopoietic lineage zinc finger protein), Ddx41 (DEAD-box helicase 41), Taf15 (TATA-box binding protein associated gactor 15), Fus (heterogeneous nuclear ribonucleoprotein P2), Rnf31 (ring finger protein 31), Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1), Hnrnpl (heterogeneous nuclear ribonucleoprotein L), Thoc4 (THO complex subunit 4 protein), Syncrip (synaptotagmin binding cytoplasmic RNA interacting protein), Srrt (serine / arginine-rich splicing factor), Tardbp (TAR DNA-binding protein), Poldip3 (DNA polymerase delta interacting protein 3), and Setd1a (SET domain containing 1A) and A1cf (APOBEC1 It is one or more proteins selected from a group consisting of Complementation Factors.

[0032] Accordingly, the present invention provides a method for providing information regarding the diagnosis of an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and an RNA splicing regulatory factor in a biological sample isolated from an individual, wherein the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

[0033] The above-mentioned autoimmune disease may specifically be lupus, and more specifically, systemic lupus erythematosus (SLE), but is not limited thereto.

[0034] The RNA splicing regulatory factor may more preferably be one or more proteins selected from the group consisting of Rnf31 (ting finger protein 31), Tardbp (TAR DNA-binding protein), and Setd1a (SET domain containing 1A), but is not limited thereto.

[0035] According to a specific embodiment of the present invention, the method is a method for diagnosing an autoimmune disease, cancer, or inflammation when the binding strength of ETS1 and RNA splicing regulatory factors is reduced.

[0036] In this specification, the term “increase in binding strength” means an increase in the binding strength between transcription factor ETS1 and RNA splicing regulators. Specifically, it may mean a state in which the binding strength is increased by 10% or more compared to a control group of healthy people, more specifically a state in which it is increased by 20% or more, and even more specifically a state in which it is increased by 30% or more.

[0037] In this specification, the term “reduction in binding strength” means a decrease in the binding strength between transcription factor ETS1 and RNA splicing regulators. Specifically, it may mean a state in which the binding strength is reduced by 10% or more compared to a control group of healthy people, more specifically a state in which it is reduced by 20% or more, and even more specifically a state in which it is reduced by 30% or more.

[0038] According to another aspect of the present invention, the present invention provides a screening method for a candidate substance for treating an autoimmune disease, comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulator in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for treating an autoimmune disease to said individual; and (c) remeasuring the binding strength of said ETS1 and the RNA splicing regulator.

[0039] According to a specific embodiment of the present invention, the RNA splicing regulatory factor is Helz (hematopoietic lineage zinc finger protein), Ddx41 (DEAD-box helicase 41), Taf15 (TATA-box binding protein associated gactor 15), Fus (heterogeneous nuclear ribonucleoprotein P2), Rnf31 (spin finger protein 31), Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1), Hnrnpl (heterogeneous nuclear ribonucleoprotein L), Thoc4 (THO complex subunit 4 protein), Syncrip (synaptotagmin binding cytoplasmic RNA interacting protein), Srrt (serine / arginine-rich splicing factor), Tardbp (TAR DNA-binding protein), Poldip3 (DNA polymerase delta interacting protein 3), and Setd1a (SET domain containing 1A) and A1cf (APOBEC1 Complementation Factor). It is one or more proteins selected from the composed group.

[0040] Accordingly, the present invention provides a screening method for a candidate substance for treating an autoimmune disease, comprising: (a) measuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as RNA splicing regulators in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for treating an autoimmune disease to said individual; and (c) remeasuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as RNA splicing regulators in said ETS1.

[0041] The above-mentioned autoimmune disease may specifically be lupus, and more specifically, systemic lupus erythematosus (SLE), but is not limited thereto.

[0042] The RNA splicing regulatory factor may more preferably be one or more proteins selected from the group consisting of Rnf31 (ting finger protein 31), Tardbp (TAR DNA-binding protein), and Setd1a (SET domain containing 1A), but is not limited thereto.

[0043] The biological sample isolated from the above individual may preferably be a CD4+ T cell, but is not limited thereto.

[0044] The above method may determine that the candidate substance is a substance for treating autoimmune diseases when the binding strength of ETS1 and the RNA splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a).

[0045] According to another aspect of the present invention, the present invention provides a screening method for a candidate substance for cancer treatment comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulator in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for cancer treatment to said individual; and (c) remeasuring the binding strength of said ETS1 and the RNA splicing regulator.

[0046] According to a specific embodiment of the present invention, the RNA splicing regulatory factor is Helz (hematopoietic lineage zinc finger protein), Ddx41 (DEAD-box helicase 41), Taf15 (TATA-box binding protein associated gactor 15), Fus (heterogeneous nuclear ribonucleoprotein P2), Rnf31 (spin finger protein 31), Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1), Hnrnpl (heterogeneous nuclear ribonucleoprotein L), Thoc4 (THO complex subunit 4 protein), Syncrip (synaptotagmin binding cytoplasmic RNA interacting protein), Srrt (serine / arginine-rich splicing factor), Tardbp (TAR DNA-binding protein), Poldip3 (DNA polymerase delta interacting protein 3), and Setd1a (SET domain containing 1A) and A1cf (APOBEC1 Complementation Factor). It is one or more proteins selected from the composed group.

[0047] Accordingly, the present invention provides a screening method for a candidate substance for cancer treatment comprising: (a) measuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as ETS1 and RNA splicing regulators in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for cancer treatment to said individual; and (c) remeasuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as ETS1 and RNA splicing regulators.

[0048] The RNA splicing regulatory factor may more preferably be one or more proteins selected from the group consisting of Rnf31 (ting finger protein 31), Tardbp (TAR DNA-binding protein), and Setd1a (SET domain containing 1A), but is not limited thereto.

[0049] The biological sample isolated from the above individual may preferably be a CD4+ T cell, but is not limited thereto.

[0050] The above method may determine that the candidate substance is a substance for cancer treatment when the binding strength of ETS1 and the RNA splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a).

[0051] According to another aspect of the present invention, the present invention provides a screening method for a candidate substance for treating inflammation, comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulator in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for treating inflammation to said individual; and (c) remeasuring the binding strength of said ETS1 and the RNA splicing regulator.

[0052] According to a specific embodiment of the present invention, the RNA splicing regulatory factor is Helz (hematopoietic lineage zinc finger protein), Ddx41 (DEAD-box helicase 41), Taf15 (TATA-box binding protein associated gactor 15), Fus (heterogeneous nuclear ribonucleoprotein P2), Rnf31 (spin finger protein 31), Hnrnph1 (heterogeneous nuclear ribonucleoprotein H1), Hnrnpl (heterogeneous nuclear ribonucleoprotein L), Thoc4 (THO complex subunit 4 protein), Syncrip (synaptotagmin binding cytoplasmic RNA interacting protein), Srrt (serine / arginine-rich splicing factor), Tardbp (TAR DNA-binding protein), Poldip3 (DNA polymerase delta interacting protein 3), and Setd1a (SET domain containing 1A) and A1cf (APOBEC1 Complementation Factor). It is one or more proteins selected from the composed group.

[0053] Accordingly, the present invention provides a screening method for a candidate substance for treating inflammation, comprising: (a) measuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as ETS1 and RNA splicing regulators in a biological sample isolated from an individual other than a human; (b) administering a candidate substance for treating inflammation to said individual; and (c) remeasuring the binding strength of one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf as ETS1 and RNA splicing regulators.

[0054] The RNA splicing regulatory factor may more preferably be one or more proteins selected from the group consisting of Rnf31 (ting finger protein 31), Tardbp (TAR DNA-binding protein), and Setd1a (SET domain containing 1A), but is not limited thereto.

[0055] The biological sample isolated from the above individual may preferably be a CD4+ T cell, but is not limited thereto.

[0056] The above method may determine that the candidate substance is an anti-inflammatory substance when the binding strength of ETS1 and the RNA splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a).

[0057] The term “candidate substance” used in reference to the screening method of the present invention refers to an unknown substance used in screening to test whether it is added to a sample containing cells expressing the protein and affects their activity or expression amount. The test substance includes, but is not limited to, compounds, nucleotides, peptides, and natural extracts. The step of measuring the binding strength, expression amount, or activity of one or more proteins selected from the group consisting of the transcription factor ETS1 and RNA splicing regulators Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf in a biological sample treated with the test substance may be performed by various expression amount and activity measurement methods known in the art.

[0058] According to another aspect of the present invention, the present invention provides a method for diagnosing an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and an RNA splicing regulatory factor in a biological sample isolated from an individual, wherein the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

[0059] According to another aspect of the present invention, the present invention provides a method for treating an autoimmune disease comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulatory factor in a biological sample isolated from an individual; (b) administering a candidate substance for treating an autoimmune disease to the individual; and (c) remeasuring the binding strength of ETS1 and the RNA splicing regulatory factor; wherein the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

[0060] According to another aspect of the present invention, the present invention provides a method for treating cancer comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulator in a biological sample isolated from an individual; (b) administering a candidate substance for cancer treatment to the individual; and (c) remeasuring the binding strength of ETS1 and the RNA splicing regulator; wherein the RNA splicing regulator is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

[0061] According to another aspect of the present invention, the present invention provides a method for treating inflammation, comprising: (a) measuring the binding strength of ETS1 and an RNA splicing regulatory factor in a biological sample isolated from an individual; (b) administering a candidate substance for treating inflammation to the individual; and (c) remeasuring the binding strength of ETS1 and the RNA splicing regulatory factor; wherein the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

[0062] The features and advantages of the present invention are summarized as follows:

[0063] (a) The present invention provides a composition for diagnosing autoimmune diseases, cancer, or inflammation, comprising a preparation for measuring the binding strength of a transcription factor and an RNA splicing regulator.

[0064] (b) The present invention is a study for effective and accurate diagnosis of inflammatory diseases, including autoimmune diseases. By discovering that the activation and differentiation of T cells can be regulated through the control of the binding strength between the transcription factor Ets1 (Protein C-ets-1) and RNA splicing regulators, it is expected to be widely used in the medical and healthcare fields, as it enables rapid, accurate, and efficient diagnosis of autoimmune diseases, cancer, or inflammation.

[0065] Figure 1 is the result of confirming the presence of ETS1 in T cells to understand the mechanism of action of ETS1 according to one embodiment of the present invention.

[0066] Figure 2 is the result of confirming the ETS1 binding protein in the nucleus of a CD4+ T cell according to one experimental example of the present invention.

[0067] Figures 3a and 3b are results confirming that, according to one experimental example of the present invention, ETS1 strongly binds to proteins related to chromatin remodeling, cell cycle and transcription regulation, as well as RNA processing.

[0068] Figure 4 is a result confirming that ETS1 interacts with the components of the RNA splicing complex according to one experimental example of the present invention.

[0069] Figure 5 is a schematic diagram of an experiment comparing RNA-seq between ETS1-deficient CD4+ T cells and normal T cells according to one experimental example of the present invention.

[0070] Figure 6 is the result of analyzing a differential splicing gene (DSG) through high-depth RNA-seq according to one experimental example of the present invention.

[0071] Figure 7 is a result confirming that genes associated with T cell activation have altered isoforms according to one experimental example of the present invention.

[0072] Figure 8 is the result of identifying factors that overlap with ETS1 binding proteins among the DSG upstream regulatory factors through mutual comparison between the CisBP-RNA database and ChIP-RNA according to one experimental example of the present invention.

[0073] FIGS. 9a to 9c are results confirming that, according to one experimental example of the present invention, ETS1 has a substantial effect on the splicing of major genes related to T cell activation among DSGs derived from RNA-seq.

[0074] Figure 10 is the result of analyzing the mechanism of ETS1 with the splicing of CD45(Ptprc) as an example according to one experimental example of the present invention.

[0075] The present invention will be described in more detail below through examples. These examples are intended solely to explain the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these examples according to the gist of the invention.

[0076] Examples

[0077] [Experimental Method]

[0078] 1. Immunoprecipitation (IP) for Mass Spectrometry

[0079] Immunoprecipitation (IP) combined with LC-MS / MS is a widely used method in proteomics research to identify proteins and study protein-protein interactions. Using IP technology allows for the purification of proteins of interest and the reduction of sample complexity before introduction into a mass spectrometer.

[0080] For IP and LC-MS / MS analysis, 20 mg of cell lysate from stimulated primary CD4+ T cells was immunoprecipitated with 40 µg of anti-Ets1 antibody (SantaCruz) overnight at 4°C, and then incubated for an additional 2 hours at 4°C with the addition of 100 µl of Protein A magnetic beads (Invitrogen). Each immunoprecipitate was washed three times with cell lysis buffer and three additional washes with 1X PBS. Subsequently, the precipitates were eluted in 8M urea and analyzed by LC-MS / MS.

[0081] For Co-IP, 1 mg of cell lysate from stimulated primary CD4+ T cells was immunoprecipitated overnight with 4 µg of anti-Ets1 antibody (SantaCruz), and then incubated for an additional 2 hours at 4°C after adding 20 ml of protein A magnetic beads (Invitrogen). Each immunoprecipitate was washed three times with cell lysis buffer and three additional washes with 1X PBS, after which the immunoprecipitates were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore).

[0082] 2. Digestion of IP Precipitated Proteins for Micro-LC / LC-MS / MS Analysis

[0083] For the digestion and LC-MS / MS analysis of IP samples (precipitated proteins), the samples were diluted fivefold with 50 mM ammonium bicarbonate (pH 8.0) and 8 M urea, reduced by adding tris(2-carboxyethyl)phosphine hydrochloride for 30 minutes at room temperature, carboxy-amidomethylated with 10 mM iodoacetamide for 30 minutes at room temperature in the dark, and endoproteinase Lys-C (Promega) was added to achieve a final substrate:enzyme ratio of 100:1, and incubated at 37°C for 12 hours. Subsequently, the solution digested with Lys-C was diluted fourfold with 50 mM ammonium bicarbonate (pH 8.0) and 22 mM CaCl2 was added. Modified trypsin (Promega) was added at a final substrate:enzyme ratio of 100:1, and trypsin digestion was performed by incubating at 37°C for 14 hours. For LC-MS / MS analysis, a single-phase microcapillary column was fabricated using a 100 mm inner diameter fused silica capillary tubing pulled out with a 5 mm inner diameter tip using a CO2 laser puller (Sutter Instruments, P-2000). The capillary column was packed sequentially using a home-made high-pressure column loader, consisting of a 7.5 cm 5-mm inner diameter Polaris C18-A (Metachem), a 4.5 cm 5-mm inner diameter Partisphere strong cation exchange (Whatman), and then another 3.5 cm Polaris C18-A. The column was equilibrated with 5% CAN and 0.1% formic acid solution, and 10–25 mg of protein digests were directly injected into the capillary column. Buffer A (5% ACN and 0.1% formic acid), Buffer B (80% ACN and 0.1% formic acid), and Buffer C (500 mM ammonium acetate, 5% ACN and 0.1% formic acid) buffer solutions were used to separate the protein digests. SCX / RPLC peptide separation was performed in six steps.The first step, 120 min, consisted of a 95-min gradient from 0 to 100% Buffer B and a 25-min retention period in 100% Buffer B. The subsequent five steps, also 120 min, proceeded with 55% Buffer B from 15 to 120 min. The percentage of Buffer C in the second step was 5% from 10 to 15 min, while steps 3 through 6 proceeded at 10, 25, 50, and 100%, respectively, from 5 to 9 min. Peptides eluted from the capillary column were electrosprayed using an LCQ Deca XP Plus IT mass spectrometer (Thermo Finnigan) with a terminal spray voltage of 2.4 kV. During the LC separation, a cycle consisting of one full scan (400–1400 m / z) followed by three data-dependent MS / MS scans at 35% normalized collision energy was repeatedly performed. Subsequently, the original data was compared with the IPI mouse v3.60 reference sequence database using the SEQUEST algorithm in Bioworks (version 3.1).

[0084] 3. Protein Data Processing and Quantification

[0085] An output file generated using DTASelect v2.0 was submitted to filter significant peptides with a global false discovery rate (FDR = 5%). The DTASelect filtering options were provided as follows: p 1: minimum peptide criterion per locus = 1, y 2: include only fully trypsin peptides, hidedecoy: do not display peptides identified as decoy sequences, t 0: do not remove duplicate spectra for each sequence, C 16: set highest charge state, i 0: set minimum ratio of observed fragment ions, s 1000: set maximum Sp rank.

[0086] Filtered peptides are normalized spectral index (SI), one of the spectral counting methods N Quantified by the ) method, and the SI of a given protein in a specific sample N It was derived from the spectral index (SI). The SI is calculated by summing the intensities of all identified peptides belonging to the corresponding protein, and then the SI of a specific protein is obtained by dividing the total SI of the sample by the protein length. N This is derived. The SI of each sample N The values ​​were sorted, log2 converted, and normalized by quartile normalization. A two-sample t-test and a median fold test were performed on each comparison set, and the p-values ​​of each test were combined into a total p-value using an unweighted integration method. In this invention, proteins satisfying one of the following two criteria were selected as Ets1 interactors under specific conditions:

[0087] 1) Overall p-value < 0.05 and median folding test p-value < 0.1 under the corresponding conditions; or,

[0088] 2) Detected only in Ets1 under specific conditions and not detected under those conditions and other conditions.

[0089] 4. Enrichment Analysis and Protein Network Visualization

[0090] Ets1 interactors were annotated in the Amigo database under the term Gene Ontology Cellular Component (GOCC). Proteins annotated as 'nucleus' (GO:0005634) were filtered to focus on nuclear Ets1 interactors and were further analyzed. Additionally, functional enrichment analysis was performed using DAVID software. Gene Ontologies belonging to GOCCs, Gene Ontology Biological Processes (GOBP), and Kegg pathways enriched with a p-value < 0.1 were considered significantly enriched ontology or pathway. Functional protein network maps were visualized using Cytoscape. In this network, nodes represent nuclear proteins among Ets1 interactors, and edges represent protein-protein interactions from MetaCore™ (ver 6.7). All types of interactions from MetaCore™, excluding 'transcriptional regulation,' were used to construct the network. Proteins sharing similar biological functions were arranged together and indicated by a background color (green). A set of proteins previously reported to interact with Ets1 was collected from MetaCore™ (ver 6.7) and the NCBI database, and functional enrichment tests and network visualizations were also performed on known and novel Ets1 interactors in the nucleus.

[0091] 5. Identification of Differential Splicing Genes (DSGs)

[0092] 5-1. Reference Genome and Gene Annotation

[0093] The mouse reference genome (GRCm38 / mm10) was used throughout the study. Gene annotations were based on the GTF format containing 32,144 genes and 306,586 exons, and all genome coordinates were mapped using the UCSC Genome Browser (http: / genome.ucsc.edu).

[0094] 5-2. RNA Sequencing

[0095] RNA samples were obtained from wild-type and Ets-1 knockout mice, and a total of six RNA-seq libraries (three biological copies per group) were prepared using the SMARTer Ultra Low Input RNA Kit for Illumina (Takara Bio). The libraries were sequenced to generate an average of 45,112,090 paired-end reads per sample. FastQC (Andrews, 2010) was used for quality control, and since adapter sequences were detected in all reads, the first 13 bases of each read were trimmed before further processing.

[0096] 5-3. Reading Differential Gene Expression Analysis

[0097] Trimmed reads were aligned to the mm10 reference genome using TopHat v2.0.10 (Trapnell et al., 2012), and transcriptome assembly and quantification were performed using Cufflinks v2.1.1. The mean mapping rate across all libraries was 95%. Differential gene expression analysis was performed using Cuffdiff, and visualization was performed using the cummeRbund R package; genes with a p-value < 0.05 were considered significantly differentially expressed. Under matched experimental conditions, a total of approximately 300 differentially expressed genes (DEGs) were identified between wild-type and Ets-1 knockout mice.

[0098] 5-4. Alternative Splicing Analysis

[0099] SpliceTrap v0.90.5 was used to evaluate differential exon usage (DEU) associated with Ets-1 knockout. SpliceTrap identifies alternative splicing events by calculating exon inclusion rates. The analysis was performed using the -c H option to include all annotated exons. This resulted in the detection of a total of 1,319 exon skipping events, including 1,223 unique exons that showed significant variation between wild-type and knockout samples.

[0100] 6. Close ligation test

[0101] Proximity-ligation (PL) analysis was performed using the Duolink In Situ Red Starter Kit (Sigma) according to the manufacturer's protocol with anti-ETS1 or anti-HnrnpL, anti-Hnrnph1, anti-DDX17, anti-HnrnpQ, anti-FUS, anti-GEMIN2, and anti-DDX41 antibodies. Relative proximity-ligation signals (PL signal / DAPI signal) were quantified using Image J software and calculated as the relative fold change compared to an untreated control.

[0102] 7. Quantification of mRNA

[0103] To measure mRNA production, total RNA was isolated using the RNeasy Mini Kit (Qiagen) or TRIzol reagent (Qiagen) and reverse transcribed using the Power cDNA Synthesis Kit (Intron). Quantitative real-time PCR was performed using SYBR Premix Ex Taq (Takara).

[0104] [Experimental Results]

[0105] 1. Confirmation of the ETS1 macromolecular complex in T cells

[0106] To understand the mechanism of action of ETS1, we sought to determine how ETS1 exists within T cells. To this end, T cells were isolated from mouse spleens and fractionated based on protein size using FPLC, followed by confirming the formation of protein complexes using antibodies against ETS1. The experimental results confirmed that ETS1 exists within T cells as protein complexes of various sizes, ranging from 2000 kDa to 160 kDa (Fig. 1).

[0107] 2. Identification of ETS1-binding proteome in the nucleus

[0108] After isolating proteins from mouse-derived T cells, the ETS1-Cofactor complex was immunoprecipitated using an ETS1 antibody, and the ETS1 interactome within the T cells was identified using liquid chromatography-mass spectrometry (LC-MS / MS). Through this, it was confirmed that ETS1 is involved in various cellular functionalities in the cytoplasm as well as in functions within the nucleus (Fig. 2). Focusing on elucidating the T cell regulatory mechanism of ETS1 as a transcription factor, research was conducted on 161 nuclear protein complexes. As a result, it was confirmed that nuclear ETS1 protein complexes strongly bind not only to previously known transcriptional regulations such as chromatin remodeling and transcription and cell cycle regulation, but also to proteins related to RNA processing (Figs. 3a and 3b). In particular, among the protein group involved in RNA processing, the proportion of splicing-related factors was found to be high, suggesting the possibility of new functions in addition to the existing functions of ETS1 (transcriptional regulation and epigenomic regulation).

[0109] 3. Validation of binding via Proximal Ligation Assay (PLA)

[0110] PLA experiments were performed to confirm physical binding with splicing factors identified by IP-MS / MS. This method verifies binding by utilizing the principle that two proteins emit light when located close to each other within a cell. The test results confirmed that ETS1 actually binds to RNA processing factors, namely Hnrnpl, HnrnpH1, DDX17, HnrnpQ, FUS, GEMIN2, and DDX41. This is significant as it experimentally verified that ETS1 interacts with the components of the RNA splicing complex (Fig. 4).

[0111] 4. Confirmation of changes in T cell RNA splicing due to ETS1 deficiency

[0112] Based on the hypothesis that ETS1 may be involved in RNA splicing, RNA-seq analysis was performed between ETS1-deficient CD4+ T cells and normal T cells (Fig. 5). During this process, differential splicing gene (DSG) analysis was possible through high-depth RNA-seq analysis (Fig. 6). When DSGs were compared under three conditions (no stimulation, αCD3 / 28 stimulation, and PMA / ionomycin stimulation), it was confirmed that splicing patterns in various genes changed upon ETS1 deficiency, and in particular, genes associated with T cell activation exhibited altered isoforms (Fig. 7). Additionally, through cross-comparison between the CisBP-RNA database and ChIP-RNA, factors overlapping with ETS1-binding proteins among the upstream regulatory factors of DSG were identified (Fig. 8). This suggests that ETS1 is functionally associated with key factors of the splicing regulatory complex, either directly or indirectly.

[0113] 5. Verification of splicing changes in major DSG genes

[0114] Among the DSGs derived from RNA-seq, the inclusion of exons for major genes related to T cell activation (MAPK3K5, MAPK9, MAP4K4, CDK2, IRAK1, etc.) was verified via RT-PCR. As a result, a clear change in the inclusion or exclusion of specific exons was observed in ETS1 knockout cells, confirming that ETS1 has a substantial effect on the splicing of these genes (Figs. 9a to 9c).

[0115] 6. ETS1 Splicing Regulation Mechanism - CD45 Gene Case Analysis

[0116] The mechanism of ETS1 was analyzed using the splicing of the representative T cell marker gene CD45 (Ptprc) as an example. Integrating ETS1 ChIP-seq and RNA-seq data revealed that ETS1 binds to the region between Exons 1 and 2 of the CD45 gene (Fig. 10). Since this region is an area where splicing events frequently occur, it is suggested that ETS1 may function to locally recruit splicing factors by binding to this site. Indeed, a distinct change in the isoform distribution of CD45 was observed upon ETS1 deficiency.

[0117] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A composition for diagnosing autoimmune diseases, cancer, or inflammation comprising a preparation for measuring the binding strength of ETS1 and an RNA splicing regulatory factor; A composition in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.

2. In Paragraph 1, A composition in which the above-mentioned autoimmune disease is Lupus.

3. A method for providing information regarding the diagnosis of an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and RNA splicing regulatory factors in a biological sample isolated from an individual. A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

4. In Paragraph 3, The above-mentioned autoimmune disease is Lupus.

5. In Paragraph 3, A method in which the biological sample isolated from the above individual is a CD4+ T cell.

6. In Paragraph 3, The above method is a method for diagnosing an autoimmune disease, cancer, or inflammation when the binding strength of ETS1 and RNA splicing regulatory factors is reduced. 7.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals other than humans; (b) a step of administering a candidate substance for treating an autoimmune disease to the above individual; and, (c) a step of remeasuring the binding strength of the ETS1 and RNA splicing regulatory factor; comprising a screening method for candidate substances for the treatment of autoimmune diseases, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

8. In Paragraph 7, A method in which the biological sample isolated from the above individual is a CD4+ T cell.

9. In Paragraph 7, The above method is, A method for determining that the candidate substance is a substance for treating autoimmune diseases when the binding strength of ETS1 and the RNA splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a) above.

10. In Paragraph 7, The above-mentioned autoimmune disease is Lupus. 11.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals other than humans; (b) a step of administering a candidate substance for cancer treatment to the above individual; and, (c) a step of remeasuring the binding strength of the ETS1 and RNA splicing regulators; comprising a screening method for a candidate substance for cancer treatment, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

12. In Paragraph 11, A method in which the biological sample isolated from the above individual is a CD4+ T cell.

13. In Paragraph 11, The above method is, A method for determining that a candidate substance is a substance for cancer treatment when the binding strength of ETS1 and the splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a) above. 14.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals other than humans; (b) a step of administering a candidate substance for treating inflammation to the above individual; and, (c) a step of remeasuring the binding strength of the above ETS1 and RNA splicing regulatory factor; a screening method for candidate substances for treating inflammation, comprising: A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Poldip3, and A1cf.

15. In Paragraph 14, A method in which the biological sample isolated from the above individual is a CD4+ T cell.

16. In Paragraph 14, The above method is, A method for determining that a candidate substance is an anti-inflammatory substance when the binding strength of ETS1 and the RNA splicing regulator in step (c) is increased compared to the binding strength of ETS1 and the RNA splicing regulator in step (a) above.

17. A method for diagnosing an autoimmune disease, cancer, or inflammation, comprising the step of measuring the binding strength of ETS1 and an RNA splicing regulatory factor in a biological sample isolated from an individual, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf. 18.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals; (b) a step of administering a candidate substance for treating an autoimmune disease to the above individual; and, (c) a step of remeasuring the binding strength of the ETS1 and the RNA splicing regulatory factor; comprising a method for treating an autoimmune disease, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf. 19.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals; (b) a step of administering a candidate substance for cancer treatment to the above individual; and, (c) a step of remeasuring the binding strength of the ETS1 and the RNA splicing regulatory factor; comprising a method for treating cancer, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf. 20.(a) A step of measuring the binding strength of ETS1 and RNA splicing regulators in biological samples isolated from individuals; (b) a step of administering a candidate substance for treating inflammation to the above individual; and, (c) a step of remeasuring the binding strength of the above ETS1 and the RNA splicing regulatory factor; comprising a method for treating inflammation, A method in which the RNA splicing regulatory factor is one or more proteins selected from the group consisting of Helz, Ddx41, Taf15, Fus, Rnf31, Hnrnph1, Hnrnpl, Thoc4, Syncrip, Srrt, Tardbp, Poldip3, Setd1a, and A1cf.